XCUR 2.69 Exicure, Inc.
| Range: | 1.44-6.0 | Vol Avg: | 1421268 | Last Div: | 0 | Changes: | -0.23 |
| Beta: | 1.28 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue May 22 2018 | Empoloyees: | 5 | ||
| CUSIP: | 30205M101 | CIK: | 0001698530 | ISIN: | US30205M2008 | Country: | US |
| CEO: | Mr. Paul Kang | Website: | https://www.exicuretx.com | ||||
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Stock Details
Positive 0.45
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), annou...
businesswire.com·Wed Sep 18 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow